{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:01Z","timestamp":1790655061595,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["15-R99-A5855"],"award-info":[{"award-number":["15-R99-A5855"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015223","name":"Danish Diabetes Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008218","name":"Gangstedfonden","doi-asserted-by":"publisher","award":["R572-A38190"],"award-info":[{"award-number":["R572-A38190"]}],"id":[{"id":"10.13039\/501100008218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jchf.2021.02.016","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T14:00:23Z","timestamp":1627308023000},"page":"550-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in\u00a0Type 2\u00a0Diabetes"],"prefix":"10.1016","volume":"9","author":[{"given":"Niels H.","family":"Brandt-Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Lav Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Rye J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.02.016_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jchf.2021.02.016_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res."},{"key":"10.1016\/j.jchf.2021.02.016_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.jchf.2021.02.016_bib4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.jchf.2021.02.016_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc17-0755","article-title":"The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction","volume":"41","author":"Sandesara","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.jchf.2021.02.016_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib7","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ajh.2010.80","article-title":"Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis","volume":"23","author":"Pierdomenico","year":"2010","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.jchf.2021.02.016_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.jchf.2021.02.016_bib10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/HJH.0000000000000280","article-title":"Greater efficacy of aldosterone blockade and diuretic reinforcement vs dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension","volume":"32","author":"Azizi","year":"2014","journal-title":"J\u00a0Hypertens."},{"key":"10.1016\/j.jchf.2021.02.016_bib11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/dom.13809","article-title":"Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial (MIRAD trial)","volume":"21","author":"Johansen","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jchf.2021.02.016_bib12","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.jchf.2021.02.016_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcmg.2015.11.005","article-title":"T1 mapping basic techniques and clinical applications","volume":"9","author":"Taylor","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Img."},{"key":"10.1016\/j.jchf.2021.02.016_bib14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1002\/sim.3639","article-title":"Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?","volume":"28","author":"Liu","year":"2009","journal-title":"Stat Med."},{"key":"10.1016\/j.jchf.2021.02.016_bib15","first-page":"116544","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial","volume":"408","author":"Brandt-Jacobsen","year":"2020","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.jchf.2021.02.016_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2008.04.069","article-title":"Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart\u00a0Failure Trial)","volume":"52","author":"Masson","year":"2008","journal-title":"J\u00a0Am Coll Cardiol."},{"key":"10.1016\/j.jchf.2021.02.016_bib17","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.jchf.2021.02.016_bib19","first-page":"59","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF."},{"key":"10.1016\/j.jchf.2021.02.016_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.jchf.2021.02.016_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2017.12.011","article-title":"Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation","volume":"115","author":"Buonafine","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol."},{"key":"10.1016\/j.jchf.2021.02.016_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/biom8030096","article-title":"Mineralocorticoid receptor and aldosterone-related biomarkers of end-organ damage in cardiometabolic disease","volume":"8","author":"Gorini","year":"2018","journal-title":"Biomolecules."},{"key":"10.1016\/j.jchf.2021.02.016_bib23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.111.187872","article-title":"Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system","volume":"59","author":"Latouche","year":"2012","journal-title":"Hypertension."},{"key":"10.1016\/j.jchf.2021.02.016_bib24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","author":"Lother","year":"2011","journal-title":"Hypertension."},{"key":"10.1016\/j.jchf.2021.02.016_bib25","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/db15-1627","article-title":"Adipocyte-specific mineralocorticoid receptor overexpression in mice is associated with metabolic syndrome and vascular dysfunction: role of redox-sensitive PKG-1 and Rho kinase","volume":"65","author":"Cat","year":"2016","journal-title":"Diabetes."},{"key":"10.1016\/j.jchf.2021.02.016_bib26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","article-title":"Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction","volume":"65","author":"Bender","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.jchf.2021.02.016_bib27","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib28","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart\u00a0Failure Efficacy and Survival Study (EP)","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","article-title":"Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER study","volume":"107","author":"Ferreira","year":"2018","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.jchf.2021.02.016_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCHEARTFAILURE.113.000665","article-title":"Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy","author":"Ellims","year":"2014","journal-title":"Circ heart Fail."},{"key":"10.1016\/j.jchf.2021.02.016_bib31","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis: The need for a reappraisal","volume":"65","author":"L\u00f3pez","year":"2015","journal-title":"J\u00a0Am Coll Cardiol."},{"key":"10.1016\/j.jchf.2021.02.016_bib32","first-page":"166","article-title":"Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis","volume":"22","author":"Kupari","year":"2013","journal-title":"J.\u00a0Heart Valve Dis."},{"key":"10.1016\/j.jchf.2021.02.016_bib33","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.jchf.2021.02.016_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/db12-0905","article-title":"Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?","volume":"62","author":"Bender","year":"2013","journal-title":"Diabetes."},{"key":"10.1016\/j.jchf.2021.02.016_bib35","first-page":"633","article-title":"Obesity-related heart failure with a preserved ejection fraction","volume":"6","author":"Packer","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF."},{"key":"10.1016\/j.jchf.2021.02.016_bib36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.jchf.2021.02.016_bib37","first-page":"2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med."}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921002134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921002134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:59:14Z","timestamp":1761973154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921002134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2213177921002134"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.02.016","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in\u00a0Type 2\u00a0Diabetes","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}